VR Logo

Forte Biosciences Inc. (FBRX) download report


Healthcare | Biotechnology & Pharma Research

Forte Biosciences Inc. (FBRX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata.

IPO Date: 13-Apr-2017

CEO & Chairman: Dr. Paul A. Wagner Ph.D.

Chief Financial Officer: Mr. Antony A. Riley CPA

Listing: NASDAQ: FBRX

Country: United States

Headquarters: Dallas, TX

Website: https://www.fortebiorx.com

Key Facts

Market cap: $18.75 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-19.47 Mln

Cash: $40.04 Mln

Total Debt: $0.00 Mln

Insider's Holding: 8.75%

Liquidity: Low

52 Week range: $1.03 - 36.85

Shares outstanding: 14,761,300

7 Years Aggregate:

  • CFO: $-154.05 Mln
  • EBITDA: $-181.75 Mln
  • Net Profit: $-216.68 Mln

Stock Performance

Time Period Forte Biosciences (FBRX) S&P BSE Sensex* S&P Small-Cap 600*
YTD-40.19-8.97-18.40
1 month-0.78-3.38-8.42
3 months-15.79-7.93-14.06
1 Year-96.410.55-17.64
3 Years-76.3510.416.75
5 Years-63.1411.456.18
10 Years--12.0510.23
As on 28-Jun-2022 *As on 29-Jun-2022
Year Forte Biosciences (FBRX) S&P Small-Cap 600 S&P BSE Sensex
2021-94.1225.2721.99
2020355.249.5715.75
2019-93.5120.8614.38
2018-19.81-9.705.87